Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection
PLOS Biology · 2023
DOI: 10.1371/journal.pbio.3002249 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Biology, 2023. Verfasst von Bach Tran Nguyen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, INSERM, IAME, F-75018, Paris, France. Hauptthemen laut MEDLINE: Antiviral Agents, Mpox, Monkeypox. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Université Paris Cité, INSERM.
Abstract (Originalsprache)
Despite use of tecovirimat since the beginning of the 2022 outbreak, few data have been published on its antiviral effect in humans. We here predict tecovirimat efficacy using a unique set of data in nonhuman primates (NHPs) and humans. We analyzed tecovirimat antiviral activity on viral kinetics in NHP to characterize its concentration–effect relationship in vivo. Next, we used a pharmacological model developed in healthy volunteers to project its antiviral efficacy in humans. Finally, a viral dynamic model was applied to characterize mpox kinetics in skin lesions from 54 untreated patients, and we used this modeling framework to predict the impact of tecovirimat on viral clearance in skin lesions. At human-recommended doses, tecovirimat could inhibit viral replication from infected cells by more than 90% after 3 to 5 days of drug administration and achieved over 97% efficacy at drug steady state. With an estimated mpox within-host basic reproduction number, R 0 , equal to 5.6, tecovirimat could therefore shorten the time to viral clearance if given before viral peak. We predicted that initiating treatment at symptom onset, which on average occurred 2 days before viral peak, could reduce the time to viral clearance by about 6 days. Immediate postexposure prophylaxis could not only reduce time to clearance but also lower peak viral load by more than 1.0 log 10 copies/mL and shorten the duration of positive viral culture by about 7 to 10 days. These findings support the early administration of tecovirimat against mpox infection, ideally starting from the infection day as a postexposure prophylaxis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Université Paris Cité, INSERM, IAME, F-75018, Paris, France.
- Skin Neglected Diseases and Sexually Transmitted Infections Section, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
- Fight Infectious Diseases Foundation, Badalona, Spain.
- Clinical Research Department, London School of Hygiene & Tropical Medicine, London, United Kingdom.
- Hospital for Tropical Diseases, London, United Kingdom.
- Division of Infection and Immunity, University College London, London, United Kingdom.
ORCID-Profile: Bach Tran Nguyen
Förderung
- Université Paris Cité, INSERM
Zitieren
APA
Nguyen, B. T., Marc, A., Suñer, C., Marks, M., Ubals, M., Hernández-Rodríguez, Á., Melendez, M. Á., Movie Group, Hruby, D. E., Russo, A. T., Mentré, F., Mitjà, O., Grosenbach, D. W., & Guedj, J. (2023). Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection. PLOS Biology. https://doi.org/10.1371/journal.pbio.3002249
Vancouver
Nguyen BT, Marc A, Suñer C, Marks M, Ubals M, Hernández-Rodríguez Á, et al. Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection. PLOS Biology. 2023. doi:10.1371/journal.pbio.3002249
BibTeX
@article{Nguyen2023,
author = {Nguyen, Bach Tran and Marc, Aurélien and Suñer, Clara and Marks, Michael and Ubals, Maria and Hernández-Rodríguez, Águeda and Melendez, María Ángeles and Movie Group, Movie Group and Hruby, Dennis E and Russo, Andrew T and Mentré, France and Mitjà, Oriol and Grosenbach, Douglas W and Guedj, Jérémie},
title = {Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection},
journal = {PLOS Biology},
year = {2023},
doi = {10.1371/journal.pbio.3002249}
}
EUVIMED